Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have been given an average recommendation of “Moderate Buy” by the eight analysts that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $10.0833.

Several brokerages have recently commented on XERS. Barclays assumed coverage on Xeris Biopharma in a research report on Monday, December 8th. They issued an “overweight” rating and a $9.00 target price for the company. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 8th. Oppenheimer reiterated an “outperform” rating and set a $18.00 target price on shares of Xeris Biopharma in a research note on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, January 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Xeris Biopharma in a report on Friday, January 9th.

Insider Buying and Selling

In other news, insider John Patrick Shannon, Jr. sold 24,907 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $7.08, for a total transaction of $176,341.56. Following the completion of the transaction, the insider directly owned 2,705,346 shares of the company’s stock, valued at approximately $19,153,849.68. This represents a 0.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Beth Hecht sold 16,667 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $7.01, for a total value of $116,835.67. Following the sale, the insider owned 1,320,176 shares in the company, valued at $9,254,433.76. The trade was a 1.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 280,217 shares of company stock valued at $2,041,841 over the last 90 days. 6.47% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Xeris Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the company. UBS Group AG boosted its holdings in shares of Xeris Biopharma by 682.4% in the third quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock valued at $14,511,000 after acquiring an additional 1,554,869 shares in the last quarter. Vanguard Group Inc. lifted its position in Xeris Biopharma by 13.8% in the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after purchasing an additional 1,358,760 shares during the period. Qube Research & Technologies Ltd lifted its position in Xeris Biopharma by 67.5% in the second quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock worth $14,429,000 after purchasing an additional 1,245,188 shares during the period. Goldman Sachs Group Inc. boosted its stake in Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares in the last quarter. Finally, CenterBook Partners LP increased its position in shares of Xeris Biopharma by 237.7% during the 2nd quarter. CenterBook Partners LP now owns 1,594,229 shares of the company’s stock valued at $7,445,000 after purchasing an additional 1,122,154 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Price Performance

NASDAQ XERS opened at $7.01 on Friday. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -70.09 and a beta of 0.52. Xeris Biopharma has a 12 month low of $3.44 and a 12 month high of $10.08. The company’s fifty day moving average price is $7.27 and its two-hundred day moving average price is $7.52.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, November 6th. The company reported $0.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.01). The firm had revenue of $74.38 million for the quarter, compared to analyst estimates of $74.19 million. As a group, analysts anticipate that Xeris Biopharma will post -0.41 EPS for the current year.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.